Revenue recognized

Rigel Pharmaceuticals·Products & Services·9 segments·Rolls up to Total Revenue

Breakdown

Segment	Q2 '24	Q3 '24	Q4 '24	Q1 '25	Q2 '25	Q3 '25	Q4 '25	Q1 '26
Gross product sales	$48.98M	$56.32M	$66.2M	$60.19M	$79.69M	$85.62M	$84.45M	$75.39M
Discounts and allowances	-$15.53M	-$17.4M	-$19.67M	-$16.64M	-$20.74M	-$21.56M	-$19.04M	-$20.47M
Delivery of drug supplies, royalties and others	$3.39M	$6.38M	$7.07M	$6.78M	$2.76M	$5.4M	$4.12M	$3.9M
Development Milestones	$0	$0	$0	$3M	—	—	—	$0
Total	$36.84M	$55.31M	$57.6M	$53.33M	$101.69M	$69.46M	$69.8M	$58.82M

Release Of Share Cost Liability is derived from annual filings.

Product sales, netView metric

Contract revenues from collaborationsView metric

Gross product salesView metric

Discounts and allowancesView metric

Development MilestonesView metric

Delivery of drug supplies, royalties and othersView metric

fostamatinibView metric

Release Of Share Cost LiabilityView metric